Leerink Partnrs Weighs in on CNTA Q3 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Leerink Partnrs issued their Q3 2025 EPS estimates for Centessa Pharmaceuticals in a note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of ($0.40) for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($2.06) EPS and FY2029 earnings at $0.49 EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04.

CNTA has been the subject of a number of other research reports. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Stock Down 8.0 %

Shares of Centessa Pharmaceuticals stock opened at $14.54 on Thursday. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a market capitalization of $1.92 billion, a PE ratio of -9.50 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The business has a 50-day moving average of $16.49 and a 200-day moving average of $16.42.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Janus Henderson Group PLC grew its holdings in shares of Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC bought a new position in Centessa Pharmaceuticals during the 4th quarter worth $20,994,000. Franklin Resources Inc. increased its position in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares during the period. Point72 Asset Management L.P. increased its position in Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after buying an additional 953,659 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the sale, the general counsel now directly owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $15.77, for a total value of $867,350.00. Following the transaction, the chief executive officer now owns 429,398 shares in the company, valued at $6,771,606.46. This trade represents a 11.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock worth $4,309,568 over the last quarter. 11.59% of the stock is owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.